EQUITY SECURITIES PORTFOLIO INVESTMENT (Tables)

3 Months Ended

Mar. 31, 2024

Investments, Debt and Equity Securities [Abstract]

Unrealized Gain (Loss) on Investments

Equity securities for the periods presented were comprised of the following:

Security Type	Cost		Gross Unrealized Gain		Gross Unrealized Loss		Fair Value
	(In thousands)
March 31, 2024:
Equity securities - other common stock	$	19,971	$	2,966	$	(19)	$	22,918
Total	$	19,971	$	2,966	$	(19)	$	22,918
December 31, 2023:
Equity securities - Life Sciences Portfolio	$	28,498	$	28,600	$	(20)	$	57,078
Equity securities - other common stock	4,925		1,080		(15)		5,990
Total	$	33,423	$	29,680	$	(35)	$	63,068

The following unrealized and realized gains or losses from our investment in the Life Sciences Portfolio are recorded in the change in fair value of equity securities and gain or loss on sale of equity securities, respectively, in the consolidated statements of operations:

	Three Months Ended March 31,
	2024		2023
	(In thousands)
Change in fair value of equity securities of public    companies	$	(28,581)	$	577
Gain on sale of equity securities of public    companies	28,581		—
Net realized and unrealized gain	$	—	$	577